Anticancer activity of heptazoline against the SCC-15 human oral cancer cells and inhibition of PI3K/AKT signalling pathway-Reference-Cited by-同舟云学术

Anticancer activity of heptazoline against the SCC-15 human oral cancer cells and inhibition of PI3K/AKT signalling pathway

Published:2022-03-24 Issue:1 Volume:15 Page:371-377
ISSN:2689-5293
Container-title:All Life
language:en
Short-container-title:All Life

Author:

Zhang Hongmei¹,Xun Wenxing¹,Guo Shaoxiong²,Wang Xiaoxia³,Liu Xiaolu¹

Affiliation:

1. Department of Stomatology, The Second Affiliated Hospital of Air Force Medical University, Xi'an, People’s Republic of China

2. Department of Oral Anatomy and Physiology& TMD and Orofacial Pain, School of Stomatology, The Air Force Medical University, Xi'an, People’s Republic of China

3. Department of Dermatology, The Second Affiliated Hospital of Air Force Medical University, Xi'an, People’s Republic of China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shanxi Province of China

Publisher

Informa UK Limited

Subject

General Agricultural and Biological Sciences,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

https://www.tandfonline.com/doi/pdf/10.1080/26895293.2022.2052191

Reference20 articles.

1. Smoking and disease

2. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting

3. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral Health and Nutraceutical Agents;International Journal of Molecular Sciences;2024-09-09

2. Caspase-3 Activators as Anticancer Agents;Current Protein & Peptide Science;2023-12